Key Highlights:
- Mandatory cash offer by chief executive’s family vehicle closed with 56.67% control
- FY2025 Revenue up 37% to EGP 7.9bn, with EBITDA Margin rising to 34.9%
- Q1 2026 revenue up 31% and net profit up 78% in local currency
- Independent directors said the Offer Price was below fair value
- Bidco has warned of a possible delisting if its stake reaches 75%
Integrated Diagnostics Holdings Plc (LSE:IDHC) has just come through one of the more unusual Takeover battles on the London Stock Exchange this year. Its own chief executive, Dr Hend El Sherbini, through family vehicle Hena Holdings, launched a mandatory cash offer at US$0.50 per share that the independent directors condemned as pitched at a discount to the market price. The offer nonetheless went unconditional on 28 July 2026 and closed on 12 August 2026 with the bidder controlling roughly 56.67% of the company.
That leaves a majority-controlled, still-listed diagnostics Business with fast-growing Egyptian-pound earnings, a minority free float and an explicit warning that a delisting could follow if the controlling Shareholder reaches 75%. The question for healthcare investors is whether operational momentum or the shrinking free float defines the story from here.
Mandatory offer closes with Hena Holdings in control
The chain of events began on 23 June 2026, when Hena Holdings Ltd, owned by Dr El Sherbini and her mother Dr Moamena Abdul Wahab Kamel, bought 126,000,000 IDH shares from Actis IDH Limited, an entity controlled by Elliott Investment Management. That purchase triggered a mandatory cash offer under Rule 9 of the Takeover Code for the remaining shares at US$0.50 each.
The offer document, published on 8 July 2026, made clear this was an unrecommended bid. The Independent Directors, including Lord Anthony St John and Yvonne Sillhart, unanimously advised shareholders not to accept, noting that the price “represents a discount of approximately 11.2% to the Closing Price of US$0.563” on 22 June 2026, and that it “not only fails to reflect any premium for control but is itself set at a material discount to the prevailing market price”.
The only condition was acceptances taking Bidco above 50%. On 29 July 2026 IDH announced valid acceptances covering 40,631,301 shares, or 6.98% of the issued capital. Added to the 288,445,383 shares Bidco and its concert parties already held, that gave control of 56.60% and the offer was declared unconditional. The final update on 13 August 2026 put the total at 329,447,709 shares, approximately 56.67%, after the offer closed on 12 August.
The offer document said there were no plans to change IDH’s strategy, headquarters or employment terms. However, if Bidco were to reach 75% it “intends to delist IDH from the London Stock Exchange”, warning that non-accepting shareholders “would hold shares in an unlisted and Illiquid vehicle”, with non-executive directors resigning. No relationship agreement is in place between Bidco and the company.
IDH describes itself as a woman-led, fully integrated medical diagnostics provider. It runs pathology laboratories and radiology centres across Egypt, Jordan, Nigeria, Sudan and Saudi Arabia under seven brands, and according to its website served around 8.9 million patients and performed 39.2 million tests in 2024.
Revenue comes from fee-per-test diagnostics for walk-in patients, referrals, corporate contracts and hospital clients. Egypt accounts for roughly 85% of revenues according to the offer document, so results are reported in Egyptian pounds even though the shares are quoted in US dollars in London. The branch network stood at 767 locations at the end of 2025. IDH bought a further 49% of Biolab KSA in December 2024 and expanded its Egyptian radiology and radiotherapy footprint in June 2025.
FY2025 and Q1 2026: strong growth in local currency
For the year to 31 December 2025, IDH reported revenue of EGP 7.9bn, up 37% from EGP 5.7bn in FY2024. Gross Profit rose 54% to EGP 3.4bn, a 42.7% margin, while EBITDA climbed 61% to EGP 2.7bn, lifting the EBITDA margin to 34.9% from 29.7%. Adjusted net profit grew 79%. Tests performed rose 11% and average revenue per test 24%. The board declared a Dividend of US$0.0085 per share for the year.
The first quarter of 2026, reported on 20 May 2026, kept up the pace. Revenue rose 31% to EGP 2.1bn from EGP 1.6bn in Q1 2025, with test volumes up 22% and the patient base up 17% to 2.2 million. Reported net profit jumped 78% to EGP 437m from EGP 245m, although adjusted net profit, which strips out foreign-exchange gains, rose a still-substantial 36%.
Cash and net Debt figures were not available in the announcements accessible for this article, and half-year 2026 results had not appeared on the RNS archives reviewed as of 2 September 2026; last year’s interims came out on 2 September 2025.
What could drive the stock next?
The most immediate catalyst is the half-year 2026 report. If the first-quarter pattern of 30%-plus revenue growth and expanding margins has held through June, it would reinforce the Independent Directors’ argument that the Equity was worth more than US$0.50.
The second is the controlling shareholder’s next move. Bidco holds around 56.67% and has said it would seek a delisting at 75%. Further market purchases, a fresh offer at a higher price, or an explicit statement on listing intentions would all move the shares.
Operationally, the drivers are Egyptian pricing power, radiology expansion, the ramp-up of Biolab in Saudi Arabia, and any recovery in Sudan. The Egyptian pound’s path against the dollar will determine how much local-currency growth translates into US-dollar value for London shareholders.
Liquidity and governance top the list. With a family-controlled majority, no relationship agreement and a stated intention to delist at 75%, minority shareholders face the prospect of an increasingly illiquid stock or an unlisted company. The independent directors have said they would resign in a delisting scenario.
Currency is the second major risk. Roughly 85% of revenue is earned in Egyptian pounds, and the offer document cited Devaluation and geopolitical uncertainty as factors that have weighed on the share price. Reported profits have also been flattered by foreign-exchange gains, as the gap between reported and adjusted net profit growth in Q1 2026 shows.
Other risks include Egyptian Inflation and regulatory pricing pressure on tests, the exposure of the Sudanese business to conflict, execution risk in Saudi Arabia and Nigeria, and limited public information on cash and Leverage in the announcements reviewed.
IDH (LSE:IDHC) enters the second half of 2026 growing revenue at more than 30% with expanding margins, yet with a share register now dominated by its chief executive’s family vehicle following an offer the board called materially undervalued. The half-year results, due around September on past timing, will show whether operating momentum has continued. Beyond the numbers, the decisive factors are whether Hena Holdings builds towards the 75% delisting threshold, how the Egyptian pound behaves, and whether the company maintains the disclosure standards a London Main Market listing requires.






Please wait processing your request...